Literature DB >> 19559571

HB-EGF-induced VEGF production and eNOS activation depend on both PI3 kinase and MAP kinase in HaCaT cells.

Kozo Nakai1, Kozo Yoneda, Tetsuya Moriue, Junske Igarashi, Hiroaki Kosaka, Yasuo Kubota.   

Abstract

BACKGROUND: Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a member of growth factors that have been implicated in skin patho-physiology. Although endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) appear to be involved in mitogenesis and chemotaxis in epidermal keratinocytes, the activation of eNOS and VEGF production induced by HB-EGF and its signaling mechanism remains undefined.
OBJECTIVE: We examined possible signal transduction pathways by which HB-EGF leads to eNOS activation and VEGF production in human epidermal keratinocyte cell line (HaCaT cells).
METHODS: The phosphorylation of epidermal growth factor receptor (EGFR), mitogen-activated protein kinase (MAPK; p42/p44 MAPK), Akt and eNOS were examined by Western blotting analysis. VEGF production was determined by enzyme-linked immunosorbent assay. Various inhibitors were utilized to investigate the signaling mechanisms of eNOS activation and VEGF production.
RESULTS: HB-EGF-induced phosphorylation of EGFR with maximum phosphorylation at 1h. HB-EGF-induced phosphorylation of p42/p44 MAPK in a few minutes. It activated Akt with maximum phosphorylation at 1h and eNOS with maximum phosphorylation at 3h. The HB-EGF-induced eNOS activation was significantly blocked by the p42/p44 MAPK inhibitor U0126 and the phosphatidylinositol 3-kinase (P13K) inhibitor LY294002. HB-EGF increased VEGF production. The HB-EGF-induced VEGF production was blocked by U0126 and LY294002. Finally, the HB-EGF-induced activation of Akt and eNOS was suppressed by VEGF competitive antagonist, CBO-P11.
CONCLUSION: These results demonstrate that HB-EGF-induced eNOS activation depends on p42/p44 MAPK, PI3K/Akt pathways and endogenous VEGF in HaCaT cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19559571     DOI: 10.1016/j.jdermsci.2009.06.002

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  14 in total

1.  Vascularization of the dermal support enhances wound re-epithelialization by in situ delivery of epidermal keratinocytes.

Authors:  Liana M Lugo; Pedro Lei; Stelios T Andreadis
Journal:  Tissue Eng Part A       Date:  2010-12-18       Impact factor: 3.845

2.  Synergistic induction of mitogen-activated protein kinase phosphatase-1 by thrombin and epidermal growth factor requires vascular endothelial growth factor receptor-2.

Authors:  Unni M Chandrasekharan; Matthew Waitkus; Corttrell M Kinney; Alicia Walters-Stewart; Paul E DiCorleto
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-07-29       Impact factor: 8.311

3.  Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer.

Authors:  Takako Eguchi Nakajima; Narikazu Boku; Ayako Doi; Hiroyuki Arai; Takuro Mizukami; Yoshiki Horie; Naoki Izawa; Mami Hirakawa; Takashi Ogura; Takashi Tsuda; Yu Sunakawa
Journal:  Invest New Drugs       Date:  2019-04-24       Impact factor: 3.850

4.  First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors.

Authors:  Kathleen N Moore; Johanna C Bendell; Patricia M LoRusso; Anthony J Olszanski; Esther Zwick-Wallasch; Mendel Jansen; Alexander G Vandell; Giorgio Senaldi
Journal:  Invest New Drugs       Date:  2018-07-28       Impact factor: 3.850

5.  Topical insulin accelerates wound healing in diabetes by enhancing the AKT and ERK pathways: a double-blind placebo-controlled clinical trial.

Authors:  Maria H M Lima; Andréa M Caricilli; Lélia L de Abreu; Eliana P Araújo; Fabiana F Pelegrinelli; Ana C P Thirone; Daniela M Tsukumo; Ana Flávia M Pessoa; Marinilce F dos Santos; Maria A de Moraes; José B C Carvalheira; Lício A Velloso; Mario J A Saad
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

6.  Involvement of TNF-α converting enzyme in the development of psoriasis-like lesions in a mouse model.

Authors:  Kenji Sato; Mikiro Takaishi; Shota Tokuoka; Shigetoshi Sano
Journal:  PLoS One       Date:  2014-11-10       Impact factor: 3.240

Review 7.  Keratinocytic vascular endothelial growth factor as a novel biomarker for pathological skin condition.

Authors:  Ok-Nam Bae; Minsoo Noh; Young-Jin Chun; Tae Cheon Jeong
Journal:  Biomol Ther (Seoul)       Date:  2015-01-01       Impact factor: 4.634

8.  Excess HB-EGF, which promotes VEGF signaling, leads to hydrocephalus.

Authors:  Joon W Shim; Johanna Sandlund; Mustafa Q Hameed; Bonnie Blazer-Yost; Feng C Zhou; Michael Klagsbrun; Joseph R Madsen
Journal:  Sci Rep       Date:  2016-05-31       Impact factor: 4.379

9.  Specific endothelial heparin-binding EGF-like growth factor deletion ameliorates renal injury induced by chronic angiotensin II infusion.

Authors:  Fenghua Zeng; Lance A Kloepfer; Charlene Finney; André Diedrich; Raymond C Harris
Journal:  Am J Physiol Renal Physiol       Date:  2016-05-25

10.  Overexpressing IRS1 in Endothelial Cells Enhances Angioblast Differentiation and Wound Healing in Diabetes and Insulin Resistance.

Authors:  Sayaka Katagiri; Kyoungmin Park; Yasutaka Maeda; Tata Nageswara Rao; Mogher Khamaisi; Qian Li; Hisashi Yokomizo; Akira Mima; Luca Lancerotto; Amy Wagers; Dennis P Orgill; George L King
Journal:  Diabetes       Date:  2016-05-23       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.